Journal of Oncology Pharmacy Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A case of rectal adenocarcinoma presented with palatine tonsil metastasis
The most common metastatic sites of colorectal cancer are liver, lung, peritoneum and lymph nodes. Metastasis of colorectal carcinoma to palatine tonsil is rarely seen. To our knowledge, only 11 patients were documented in English literature. Atypical metastases can sometimes lead to misdiagnosis. Precise diagnosis of atypical metastases requires a careful physical examination, good imaging method and comprehensive pathological evaluation. Here, we report a case of rectal adenocarcinoma presented with palatine tonsil metastasis. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Tonyali, O., Sumbul, A. T., Ozturk, M. A., Koyuncuer, A., Ekiz, F. Tags: Case Reports Source Type: research

Capecitabine-induced ventricular fibrillation arrest: Possible Kounis syndrome
We report the case of capecitabine-induced ventricular fibrillation arrest, possibly secondary to type I Kounis syndrome. A 47-year-old man with a history of T3N1 moderately differentiated adenocarcinoma of the colon, status-post sigmoid resection, was started on adjuvant capecitabine approximately five months prior to presentation of cardiac arrest secondary to ventricular fibrillation. An electrocardiogram (EKG) revealed ST segment elevation on the lateral leads and the patient was taken emergently to the cardiac catheterization laboratory. The catheterization revealed no angiographically significant stenosis and coronar...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Kido, K., Adams, V. R., Morehead, R. S., Flannery, A. H. Tags: Case Reports Source Type: research

Bortezomib-induced acute pancreatitis: Case report and review of the literature
We describe the case of a patient with multiple myeloma who developed acute pancreatitis after treatment with bortezomib, a proteasome inhibitor commonly used in the treatment of this disease. We reviewed the available medical literature on this topic, and found other seven similar cases, all after intravenous bortezomib. Our case is the first one occurring with the subcutaneous route of administration. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Talamo, G., Sivik, J., Pandey, M. K., Mir, M. A. Tags: Case Reports Source Type: research

Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections
We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Saunders, I. M., Lahoti, A., Chemaly, R. F., Trevino, C., Westmoreland, M., Hosing, C. Tags: Case Reports Source Type: research

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin
We report a case of oxaliplatin-induced hypersensitivity reaction manifesting as fever but with unusual presentation than the aforementioned features. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Khurana, A., Mitsis, D., Kowlgi, G. N., Holle, L. M., Clement, J. M. Tags: Case Reports Source Type: research

Can fentanyl transdermal patches prevent the cutaneous hyperpigmentation related to radiotherapy in patients with cancer?
Dermatologic adverse effects related to radiotherapy are one of the most important cosmetic problems and affect the quality of life in patients with cancer. In a male patient with non-small cell lung cancer who received palliative radiotherapy, the hyperpigmentation related to radiotherapy was examined two months later except for fentanyl transdermal patch area. The inhibitory effect of fentanyl on cell cycle may prevent hyperpigmentation related to radiotherapy. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Mutlu, H. Tags: Case Reports Source Type: research

Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma
Autoimmune hepatitis is a rarely seen autoimmune paraneoplastic syndrome of thymic carcinoma. Chemotherapy may be an effective choice in the treatment of primary tumor and paraneoplastic disorder. In this case, we report a 32-year-old man presented with increased liver enzymes and cholestasis with a history of thymoma surgically removed four years ago. Liver biopsy showed chronic active autoimmune hepatitis. Computed tomography scan showed pulmonary metastases and pleural mass as a recurrence of thymic carcinoma, proven by biopsy. After four cycles of cisplatin plus adriamycin plus cyclophosphamide plus vincristine and six...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Kivrak Salim, D., Mutlu, H., Karakurt Eryilmaz, M., Yalcin Musri, F., Tural, D., Coskun, H. S. Tags: Case Reports Source Type: research

The role of screening and monitoring for bleomycin pulmonary toxicity
Bleomycin-induced pulmonary toxicity can have a significant impact on patient outcomes. However, no guidelines for ideal screening and monitoring are available. This paper reviews the literature to identify the best way to monitor and reduce patient risk for bleomycin pulmonary toxicity. We have created evidence-based guidelines to help healthcare professionals identify patient risk factors and provide appropriate assessment and monitoring for patients receiving bleomycin therapy. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Shippee, B. M., Bates, J. S., Richards, K. L. Tags: Review Articles Source Type: research

A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis
Fluoroquinolone prophylaxis is indicated to prevent neutropenic fever in patients with acute leukemia. However, fluoroquinolone use has been associated with development of multi-drug-resistant Pseudomonas aeruginosa and extended spectrum β-lactamase producing gram-negative bacilli. Due to a presumed risk of multi-drug resistance associated with fluoroquinolone prophylaxis, patients admitted to our hospital with neutropenic fever receive empiric carbapenem therapy until cultures are negative for 72 h or identification of an organism. Our study seeks to identify the incidence of multi-drug-resistant organism colonizatio...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Nguyen, A., Heil, E., Patel, N., Duffy, A., Gilmore, S. Tags: Review Articles Source Type: research

Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease
There have been a number of recent advances in the treatment of patients with relapsed and refractory multiple myeloma. However, despite additional FDA-approved therapies including carfilzomib and pomalidomide as well as clinical trials investigating new combinations of existing treatments, multiple myeloma remains an incurable disease. New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, S...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Ashjian, E., Redic, K. Tags: Review Articles Source Type: research

Idelalisib- a PI3K{delta} targeting agent for B-cell malignancies
Idelalisib, the first in-class phosphotidlyinositol 3-kinase delta (PI3K) inhibitor, was approved by the US Food and Drug Administration in July 2014. It simultaneously received breakthrough therapy designation in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL) as well as accelerated approval as monotherapy for the treatment of relapsed follicular lymphoma and relapsed small lymphocytic lymphoma. In a pivotal phase III study of 220 patients with relapsed CLL, the overall response rate of patients who received rituximab plus idelalisib was 81%. The median progression-free survival...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Hewett, Y. G., Uprety, D., Shah, B. K. Tags: Review Articles Source Type: research

Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation
Conclusion An initial flat tacrolimus dose of 1 mg IV daily is a suboptimal approach to achieve therapeutic levels at this institution. A dose of 1.6 mg or 2 mg IV daily is a reasonable alternative to the current institutional practice. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Butts, A. R., Brown, V. T., McBride, L. D., Bolanos-Meade, J., Bryk, A. W. Tags: Original Articles Source Type: research

Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions
We report 14 cases of metastatic non-small-cell-lung-cancer patients who were premedicated with a single dose of dexamethasone 20 mg prior to pemetrexed or pemetrexed-based chemotherapy. None of these patients reported a grade 3 or above skin reactions over the course of their treatments. These findings suggest that a single dose of dexamethasone 20 mg may be an alternative premedication regimen in patients with metastatic non small cell lung cancer receiving pemetrexed or pemetrexed-based chemotherapy. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Elsoueidi, R., Lander, M. J., Richa, E. M., Adane, E. D. Tags: Original Articles Source Type: research

Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients
Conclusion Cancer patients receiving once daily enoxaparin for the treatment of acute PE may be at increased risk of recurrent PE and clinically overt bleeding. Larger randomized trials are needed to confirm the results of this study. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: King, A. C., Ma, M. Q., Chisholm, G., Toale, K. M. Tags: Original Articles Source Type: research

Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institutions experience
Conclusions Pertuzumab, trastuzumab, and taxane therapy seems to confer progression-free survival benefit for previously treated metastatic breast cancer. The use of the dual anti-HER2 antibodies, pertuzumab and trastuzumab, in addition to cytotoxic chemotherapy agents for previously treated metastatic breast cancer should be further evaluated. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Dao, B. D., Ho, H., Quintal, L. N. Tags: Original Articles Source Type: research